alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
From: amerstorage@cpros.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 7:12:20 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

donna huttema

Grants Pass, OR 97526
Before the First Division,

November 13, 1968

No. P68/485.

protests 67/9368, etc. (New York).

#### R. H. Macy & Co., Inc. *v.*United States,

Newman, J.

In accordance with stipulation of counsel that the merchandise covered by the foregoing protests consists of folding doors similar in all material respects to those the subject of *Gitkin Co.*v. *United States*(58 Cust. Ct. 383, C.D. 2997), the claim of the plaintiff was sustained.
EXHIBIT
32.2








CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO SECTION 906


OF
THE SARBANES-OXLEY ACT OF 2002





In
connection with the Annual Report of GMS Capital Corp., (the “Company”) on Form
10-K for the year ended December 31, 2009 as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, George
Metrakos, Principal Financial Officer of the Company, certify,
pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of 2002, That to the best of my knowledge:





(1)           
The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2)           
The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.








GMS
CAPITAL CORP.


By:
      /s/ George MetrakosGeorge
      MetrakosPrincipal
      Financial OfficerMarch 15, 2010
No. 62744.

#### Adolph Goldmark & Sons Corp. *v.*United States,

protest 58/11829-9911 (Chicago).

Opinion by

Johnson, J.

It was stipulated that the dutiable weight of the bottles in question were, in fact, the weights named in the invoice specifications, that is, 6)4 pounds per carton for the 7-ounce size; 7)4 pounds per carton for the 12-ounce size; and *12%*pounds per carton for the 25-ounce size. In view of the stipulation, it was held that the glass bottles were properly dutiable at the appropriate rates under paragraphs 217 and 810, as modified, on the basis of the stipulated weights.
[Federal Register Volume 88, Number 185 (Tuesday, September 26, 2023)]
[Notices]
[Page 66011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20867]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Genomics Centers for Infectious 
Diseases (U19 Clinical Trial Not Allowed).
    Date: October 24-25, 2023.
    Time: 10:00 a.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F21B, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F21B, 
Rockville, MD 20852, 240-669-5026, <a href="/cdn-cgi/l/email-protection#e18980938893888c87a18f88808885cf8f8889cf868e97"><span class="__cf_email__" data-cfemail="0f676e7d667d6662694f61666e666b2161666721686079">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: September 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20867 Filed 9-25-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
null

2017-05-12

374.0899

eng - Argued: 2017-05-12. Docket number: 16-2507
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                             777
<SECURITIES>                                         0
<RECEIVABLES>                                  130,763
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               182,080
<PP&E>                                       1,592,423
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               2,222,758
<CURRENT-LIABILITIES>                          121,342
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,212
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 2,222,758
<SALES>                                              0
<TOTAL-REVENUES>                               146,722
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               110,464
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              31,387
<INCOME-PRETAX>                                  4,871
<INCOME-TAX>                                     2,143
<INCOME-CONTINUING>                              2,728
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,728
<EPS-PRIMARY>                                      .02
<EPS-DILUTED>                                      .02
        

</TABLE>
EXHIBIT 31(b)

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Digamber Naswa, certify that:  

 

1. I have reviewed this report on Form 10-QSB (“Report”) of WWA Group, Inc.;  

 

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;   

 

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the period presented in this Report;   

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) for the small business issuer and have:  

 

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this Report is being prepared;   

 

b) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this Report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and  

 

c) Disclosed in this Report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and  

 

5. I have disclosed based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):   

 

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and   

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal controls over financial reporting. 

 

Date: August 13, 2007  

 

 

/s/ Digamber Naswa 

Digamber Naswa, Chief Financial Officer
IV 

110TH CONGRESS 

1ST SESSION H. RES. 293 

Supporting the goals and ideals highlighted through National Volunteer Week. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 29, 2007 

Ms. SHEA-PORTER submitted the following resolution; which was referred to 

the Committee on Education and Labor 

RESOLUTION 

Supporting the goals and ideals highlighted through National 

Volunteer Week. 

Whereas National Volunteer Week began in 1974 when President Nixon signed an Executive order establishing the 

week as an annual celebration of volunteering, and since 

then, every United States President has signed a proclamation promoting National Volunteer Week; 

Whereas National Volunteer Week will be observed during 

the week of April 15 through 21, 2007; 

Whereas the National Volunteer Week theme, ‘‘Inspire By 

Example’’, truly reflects the power volunteers have to inspire the people they help and to inspire others to serve; 

Whereas about 61.2 million people volunteered through or for 

an organization at least once between September 2005 

and September 2006, according to a recent survey by the 


bajohnson on PROD1PC60 with BILLS
2 

•HRES 293 IH 

United States Bureau of Labor Statistics, and the proportion of people who volunteered was 26.7 percent, more 

than a quarter of the total United States population; 

Whereas the estimated dollar value of volunteer time was 

$18.04 in 2005, according to the latest information provided by Independent Sector, a nonpartisan leadership 

forum, and the coalition estimates the value of volunteer 

time for 2005 to be $280 billion; 

Whereas volunteers have contributed to the enhancement and 

improvement of communities across the United States, 

especially with respect to the aftermath of the hurricanes 

on the Gulf Coast; and 

Whereas National Volunteer Week will continue to build 

awareness of the role that volunteers play in local, national, and international communities, and their commitment and dedication to improving lives, strengthening 

communities, and fostering civic engagement through 

service and volunteering: Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) supports the goals and ideals highlighted 

3 through National Volunteer Week; 

4 (2) acknowledges the diligent efforts of our 

5 major federally funded community service and volun6 teer programs; 

7 (3) recognizes with gratitude the contributions 

8 of the millions of dedicated and caring individuals 

9 who have chosen to serve others through vol10 unteerism; and 


bajohnson on PROD1PC60 with BILLS
3 

•HRES 293 IH 

1 (4) encourages all American people, of any age 

2 and background, to seek out opportunities to serve 

3 through volunteerism. 

Æ 


bajohnson on PROD1PC60 with BILLS
Exhibit 31.3



CERTIFICATION



I, Alessandro Sodi, certify that:



1. 	I have reviewed
this annual report on Form 10-K of Diligent Board Member Services, Inc.;



2. 	Based on my
knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report.





|Date: April 30, 2013 |  |                                                                                                    
|-------------------- |  | ---------------------------------------------------------------------------------------------------
|                     |  |                                                                                                    
|                     |  | /s/ Alessandro Sodi                                                                                
|                     |  | Alessandro Sodi
        President and Chief Executive Officer
        (Principal Executive Officer)
SERVED APRIL 12, 2010 v:Pl CF iR,\'JS?ORM 

U.S. DEPARTMENT OF TRANSPORTATION 

OFFICE OF HEARINGS 

WASHINGTON, DC 

IN THE MATTER OF 

HALLOCHEM PHARMA CO., LTD 

FAA DOCKET NO. CPlONEOOOl 

(Civil Penalty Action) 

DMS NO. FAA-2010-0197 

NOTICE OF ASSIGNMENT OF PROCEEDING 

This proceeding (heretofore designated as Case No. 2009NE700225) has been assigned 

to Administrative Law Judge Isaac D. Benkin. All future pleadings and other communications 

regarding this proceeding shall be served on the Judge, the FAA Hearing Docket, and the other 

persons named in the attached Service List. 

Attachment - Service List 

Rjpmie A. Yoder 

Chief Administrative Law, 
FAA Docket No. CPlONEOOOl 

(Civil Penalty Action) 

SERVICE LIST 

ORIGINAL & ONE COPY 

Hearing Docket 

Federal Aviation Administration 

800 Independence Avenue, S.W. 

Washington, DC 20591 

Attention Hearing Docket Clerk, AGC-430 

Wilbur Wright Building - Room 2014^ 

ONE COPY 

He Xu, Respondent's Counsel 

Deheng Law Firm Shenzhen Office 

11/F, Tower B, Anlian Plaza, 4018 

Jintian Road, Futian District, Shenzhen 

Guangdong Province, China 

TEL: 86-755-88286488 

FAX: 86-755-88286499 

e-mail address: Shenzhen(2)4ehenglaw.com 

Pallochem Pharma Co., Ltd., President 

17F, Venus Science Incubate Center 

No. 60 Xingguang Road, New North Zone 

Chongqing, China 401121 

TEL: 236-703-0808 

R. Bennett Sargent, Complainant's Counsel 

Federal Aviation Administration 

Office of the Regional Counsel 

12 New England Executive Park, ANE-7 

Burlington, MA 01803 

TEL: 781-238-7058 

FAX: 781-238-7055 

The Honorable Isaac D. Benkin 

Administrative Law Judge 

Office of Hearings, M-20 

U.S. Department of Transportation 

1200 New Jersey Avenue, S.E. 

East Building Ground Floor, Room El2-320 

Washington, D.C. 20590 

TEL: Attorney 202-366-2139; Legal Assistant: 

202-366-5121 

FAX: 202-366-7536 

' Service was by U.S. Mail. For service in person or by expedited courier, use the following address: 

Hearing Docket, Federal Aviation Administration, 600 Independence Avenue, S. W., Wilbur Wright Building -

Room 2014, Washington, DC 20591, Attn: Hearing Docket Clerk, AGC-430.
From: gbmbbj@q.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 2:44:34 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Rebecca Malas

Grants Pass, OR 97526
December 2, 1964

No. 68917.

#### Novelty Import Co., Inc. *v.*United States,

protest 59/33338.

Abstract 68780. Plaintiff’s application for rehearing denied.
Exhibit 31.1



CERTIFICATION



I, John Slatky, certify that:



I have reviewed this quarterly report on Form 10-QSB of Luxemburg Bancshares, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and

c)

Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.



Date:

August 11, 2003





/s/ John Slatky___________________________

John Slatky

Chief Executive Officer